Myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cell transplantation in children with high risk solid tumor

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Autologous bone marrow transplantation (ABMT) anti peripheral blood stem cell transplantation (PBSCT) are increasingly used to support high dose chemotherapy for solid tumors of childhood. In this review we described practical aspects of myeloablative chemotherapy rescued by ABMT, PBSCT or combination of ABMT and PBSCT for the treatment of children with high risk solid tumor, involving our experiences in 15 cases. Indication, method of harvesting bone marrow and peripheral blood stem cells, cryopreservation, transplantation, selection of antineoplastic agents for preconditioning, nutritional and G-CSF support, engraftment and outcomes for prognosis were discussed. In comparing the engraftment of stem cells between ABMT and PBSCT, the accerelation of platelet and erythrocyte recovery is less impressive, although there is a tendency to more rapid recovery of granulocyte in PBSCT group. The outcomes are distinctly improved only in patients who showed complete remission after induction chemotherapy, radiation and surgical excision. A better prognosis will be confered especially in neuroblastoma and entities of small round cell tumor. It is noteworthy that relapses can occur as distant metastasis considerable years after complete clinical remission. This may be largely contributed by contaminated malignant cells in both harvested bone marrow anti peripheral blood stem cells. There is no significant difference between the relapse rates after ABMT and PBSCT.

Original languageEnglish
Pages (from-to)1762-1770
Number of pages9
JournalJapanese Journal of Cancer and Chemotherapy
Volume22
Issue number12
Publication statusPublished - 1995

Fingerprint

Peripheral Blood Stem Cell Transplantation
Autologous Transplantation
Bone Marrow
Bone Marrow Transplantation
Drug Therapy
Neoplasms
Remission Induction
Recurrence
Induction Chemotherapy
Cryopreservation
Granulocyte Colony-Stimulating Factor
Neuroblastoma
Granulocytes
Antineoplastic Agents
Stem Cells
Blood Platelets
Erythrocytes
Radiation
Neoplasm Metastasis

Keywords

  • Autologous bone marrow transplantation
  • Myeloablative chemotherapy
  • Pediatric solid tumors
  • Peripheral blood stem cell transplantation

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

@article{cadad1fe67b440a0999f3458fec0a863,
title = "Myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cell transplantation in children with high risk solid tumor",
abstract = "Autologous bone marrow transplantation (ABMT) anti peripheral blood stem cell transplantation (PBSCT) are increasingly used to support high dose chemotherapy for solid tumors of childhood. In this review we described practical aspects of myeloablative chemotherapy rescued by ABMT, PBSCT or combination of ABMT and PBSCT for the treatment of children with high risk solid tumor, involving our experiences in 15 cases. Indication, method of harvesting bone marrow and peripheral blood stem cells, cryopreservation, transplantation, selection of antineoplastic agents for preconditioning, nutritional and G-CSF support, engraftment and outcomes for prognosis were discussed. In comparing the engraftment of stem cells between ABMT and PBSCT, the accerelation of platelet and erythrocyte recovery is less impressive, although there is a tendency to more rapid recovery of granulocyte in PBSCT group. The outcomes are distinctly improved only in patients who showed complete remission after induction chemotherapy, radiation and surgical excision. A better prognosis will be confered especially in neuroblastoma and entities of small round cell tumor. It is noteworthy that relapses can occur as distant metastasis considerable years after complete clinical remission. This may be largely contributed by contaminated malignant cells in both harvested bone marrow anti peripheral blood stem cells. There is no significant difference between the relapse rates after ABMT and PBSCT.",
keywords = "Autologous bone marrow transplantation, Myeloablative chemotherapy, Pediatric solid tumors, Peripheral blood stem cell transplantation",
author = "M. Endo and Ryuji Tanosaki",
year = "1995",
language = "English",
volume = "22",
pages = "1762--1770",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

TY - JOUR

T1 - Myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cell transplantation in children with high risk solid tumor

AU - Endo, M.

AU - Tanosaki, Ryuji

PY - 1995

Y1 - 1995

N2 - Autologous bone marrow transplantation (ABMT) anti peripheral blood stem cell transplantation (PBSCT) are increasingly used to support high dose chemotherapy for solid tumors of childhood. In this review we described practical aspects of myeloablative chemotherapy rescued by ABMT, PBSCT or combination of ABMT and PBSCT for the treatment of children with high risk solid tumor, involving our experiences in 15 cases. Indication, method of harvesting bone marrow and peripheral blood stem cells, cryopreservation, transplantation, selection of antineoplastic agents for preconditioning, nutritional and G-CSF support, engraftment and outcomes for prognosis were discussed. In comparing the engraftment of stem cells between ABMT and PBSCT, the accerelation of platelet and erythrocyte recovery is less impressive, although there is a tendency to more rapid recovery of granulocyte in PBSCT group. The outcomes are distinctly improved only in patients who showed complete remission after induction chemotherapy, radiation and surgical excision. A better prognosis will be confered especially in neuroblastoma and entities of small round cell tumor. It is noteworthy that relapses can occur as distant metastasis considerable years after complete clinical remission. This may be largely contributed by contaminated malignant cells in both harvested bone marrow anti peripheral blood stem cells. There is no significant difference between the relapse rates after ABMT and PBSCT.

AB - Autologous bone marrow transplantation (ABMT) anti peripheral blood stem cell transplantation (PBSCT) are increasingly used to support high dose chemotherapy for solid tumors of childhood. In this review we described practical aspects of myeloablative chemotherapy rescued by ABMT, PBSCT or combination of ABMT and PBSCT for the treatment of children with high risk solid tumor, involving our experiences in 15 cases. Indication, method of harvesting bone marrow and peripheral blood stem cells, cryopreservation, transplantation, selection of antineoplastic agents for preconditioning, nutritional and G-CSF support, engraftment and outcomes for prognosis were discussed. In comparing the engraftment of stem cells between ABMT and PBSCT, the accerelation of platelet and erythrocyte recovery is less impressive, although there is a tendency to more rapid recovery of granulocyte in PBSCT group. The outcomes are distinctly improved only in patients who showed complete remission after induction chemotherapy, radiation and surgical excision. A better prognosis will be confered especially in neuroblastoma and entities of small round cell tumor. It is noteworthy that relapses can occur as distant metastasis considerable years after complete clinical remission. This may be largely contributed by contaminated malignant cells in both harvested bone marrow anti peripheral blood stem cells. There is no significant difference between the relapse rates after ABMT and PBSCT.

KW - Autologous bone marrow transplantation

KW - Myeloablative chemotherapy

KW - Pediatric solid tumors

KW - Peripheral blood stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=0028877427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028877427&partnerID=8YFLogxK

M3 - Article

C2 - 7574807

AN - SCOPUS:0028877427

VL - 22

SP - 1762

EP - 1770

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -